168 related articles for article (PubMed ID: 20179231)
1. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
Hartman ZC; Wei J; Osada T; Glass O; Lei G; Yang XY; Peplinski S; Kim DW; Xia W; Spector N; Marks J; Barry W; Hobeika A; Devi G; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2010 Mar; 16(5):1466-77. PubMed ID: 20179231
[TBL] [Abstract][Full Text] [Related]
2. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Morse MA; Wei J; Hartman Z; Xia W; Ren XR; Lei G; Barry WT; Osada T; Hobeika AC; Peplinski S; Jiang H; Devi GR; Chen W; Spector N; Amalfitano A; Lyerly HK; Clay TM
Int J Cancer; 2010 Jun; 126(12):2893-903. PubMed ID: 19856307
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
4. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
6. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
7. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
9. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
10. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
13. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.
Wei WZ; Shi WP; Galy A; Lichlyter D; Hernandez S; Groner B; Heilbrun L; Jones RF
Int J Cancer; 1999 May; 81(5):748-54. PubMed ID: 10328228
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures.
Kim EK; Seo HS; Chae MJ; Jeon IS; Song BY; Park YJ; Ahn HM; Yun CO; Kang CY
Gene Ther; 2014 Jan; 21(1):106-14. PubMed ID: 24225639
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
Esserman LJ; Lopez T; Montes R; Bald LN; Fendly BM; Campbell MJ
Cancer Immunol Immunother; 1999 Feb; 47(6):337-42. PubMed ID: 10203064
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.
Cipriani B; Fridman A; Bendtsen C; Dharmapuri S; Mennuni C; Pak I; Mesiti G; Forni G; Monaci P; Bagchi A; Ciliberto G; La Monica N; Scarselli E
Hum Gene Ther; 2008 Jul; 19(7):670-80. PubMed ID: 18533895
[TBL] [Abstract][Full Text] [Related]
18. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
[TBL] [Abstract][Full Text] [Related]
19. Increasing vaccine potency through exosome antigen targeting.
Hartman ZC; Wei J; Glass OK; Guo H; Lei G; Yang XY; Osada T; Hobeika A; Delcayre A; Le Pecq JB; Morse MA; Clay TM; Lyerly HK
Vaccine; 2011 Nov; 29(50):9361-7. PubMed ID: 22001882
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
